Periostin shows promise to help fight a common form of esophageal cancer

Esophageal squamous cell carcinoma (ESCC) accounts for around 90% of esophageal cancers, especially in East Asia. New findings in indicate that periostin, or POSTN, promotes ESCC progression by enhancing cancer and stromal cell migration in cancer-associated fibroblasts (CAFs). Therefore, it may be a novel therapeutic target for treating ESCC.

  Health   Apr 9, 2024   0   47  Add to Reading List
Periostin shows promise to help fight a common form of esophageal cancer

ARE YOU TIRED OF LOW SALES TODAY?

Connect to more customers on doacWeb

Post your business here..... from NGN1,000

WhatsApp: 09031633831

ARE YOU TIRED OF LOW SALES TODAY?

Connect to more customers on doacWeb

Post your business here..... from NGN1,000

WhatsApp: 09031633831

ARE YOU TIRED OF LOW SALES TODAY?

Connect to more customers on doacWeb

Post your business here..... from NGN1,000

WhatsApp: 09031633831

Esophageal squamous cell carcinoma (ESCC) accounts for around 90% of esophageal cancers, especially in East Asia. New findings in indicate that periostin, or POSTN, promotes ESCC progression by enhancing cancer and stromal cell migration in cancer-associated fibroblasts (CAFs). Therefore, it may be a novel therapeutic target for treating ESCC.
Read Original   

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow